Skip to content

Clinical guidelines

TL;DR — Major guidelines agree on diagnostic reassessment, suicide and bipolar screening, shared decision-making, structured psychotherapy and/or antidepressants, measurement of response, continuation after remission, and escalation after adequate failure. They differ in line rankings, severity thresholds, duration language, and how quickly they position combination therapy, antipsychotic augmentation, TMS, ECT, ketamine/esketamine, and lifestyle care. CANMAT 2023 uses treatment lines and patient-partner input (Lam 2024, PMID 38711351); VA/DoD 2022 emphasizes measurement-based stepped care (McQuaid 2022, PMID 36122380); ACP 2023 recommends CBT or second-generation antidepressants as initial monotherapy for moderate-to-severe MDD and shared decisions (Qaseem 2023, PMID 36689752). Guideline agreement is not proof of high-certainty comparative evidence.

Agreement matrix

Domain Broad agreement
Assessment confirm episode, impairment, bipolarity, substances/medical causes, safety
Initial care psychotherapy, medication, or combination based on severity/preference
Monitoring standardized symptoms, function, adherence, adverse effects
Nonresponse verify adequacy and diagnosis before switch/augment
Severe/urgent specialty escalation; ECT for selected severe states
Continuation continue effective treatment after remission
Shared decisions incorporate prior response, values, access, harms

Major current documents

Body/year Region Distinctive emphasis PubMed/URL status
CANMAT 2023 update (published 2024) Canada line-based personalized management; new agents/devices Lam 2024, PMID 38711351
VA/DoD 2022 US stepped, measurement-based care across systems McQuaid 2022, PMID 36122380
ACP 2023 living guideline US CBT or second-generation antidepressant monotherapy; combination options Qaseem 2023, PMID 36689752
NICE NG222 (2022) UK less/more severe framing and shared decision menu live NICE page verified 2026-08-30 [URL in registry]
WFSBP/ASLM 2022/23 international/Australasia lifestyle intervention guidance Marx 2023, PMID 36202135

Treatment sequencing

CANMAT incorporates SSRIs/SNRIs and other antidepressants, structured psychotherapies, exercise, neuromodulation, and newer agents within a line-based framework (Lam 2024, PMID 38711351). ACP favors CBT or a second-generation antidepressant as initial monotherapy for moderate-to-severe MDD and recommends adding/switching based on response and preference (Qaseem 2023, PMID 36689752). VA/DoD emphasizes collaborative care and systematic outcome tracking (McQuaid 2022, PMID 36122380).

Controversy Why guidelines differ
Severity threshold for medication different evidence grading and preference weighting
Initial combination greater average efficacy vs added burden/cost
Antipsychotic augmentation efficacy vs metabolic/neurological harms
Ketamine/esketamine line rapid effect vs access, monitoring, long-term uncertainty
TMS timing non-systemic safety vs infrastructure/cost
Lifestyle as treatment benefit and low risk vs adherence and evidence heterogeneity

Special treatment domains

CANMAT issued specific racemic-ketamine recommendations covering selection, administration, monitoring, and the limits of long-term evidence (Swainson 2021, PMID 33174760). Consensus TMS recommendations address indication, motor-threshold procedures, seizure risk, and course delivery (McClintock 2018, PMID 28541649). WFSBP/ASLM provides explicit exercise, sleep, diet, smoking, and social-connection guidance (Marx 2023, PMID 36202135).

How to read recommendations

Recommendation strength combines evidence certainty, benefit-harm balance, values, resources, feasibility, and equity. Two guidelines can read the same effect size and choose different lines because they weight these dimensions differently. Superseded guidelines remain historically important but should not be used as current authority; chains are recorded in the guideline registry.

Guideline disagreements made explicit

Guidelines translate evidence through different health systems, resource assumptions, value judgments, and update dates. Apparent disagreement is sometimes evidentiary and sometimes operational.

Decision Convergent position Meaningful divergence
Initial moderate–severe MDD Evidence-based psychotherapy or second-generation antidepressant; shared decision NICE severity categories and CANMAT line rankings organize choices differently
Initial combination More effective on average than monotherapy Some bodies reserve it for greater severity because burden and access matter
After inadequate response Reassess diagnosis/adherence, then switch or augment Preferred augmenters and when to offer psychotherapy/TMS vary
ECT Appropriate for severe, psychotic, catatonic, urgent, or resistant presentations Consent, maintenance, and cognitive-monitoring detail differ
TMS Supported after inadequate response Line placement reflects coverage and device availability
Ketamine/esketamine Rapid-acting option under monitored conditions Racemic ketamine and licensed esketamine receive different evidentiary/legal treatment
Withdrawal Avoid abrupt cessation and individualize tapering Proportional taper detail and recognition of prolonged symptoms vary
Screening Screening requires systems for diagnosis and treatment Bodies differ on population and service prerequisites

A recommendation's grade should not be mistaken for effect magnitude: certainty, feasibility, acceptability, equity, and resource use can change strength even when the same trials are reviewed.

Additional live-search evidence ledger

The records below were added after full PubMed E-utilities retrieval on 2026-08-30. The ledger states the evidentiary role of each record and preserves the design limitation that should travel with its citation.

  • Fregni F 2021 — Evidence-Based Guidelines and Secondary Meta-Analysis for the Use of Transcranial Direct Current Stimulation in Neurological and Psychiatric Disorders. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Fregni F 2021, PMID 32710772)

  • US Preventive Services Task Force 2023 — Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement. Systematic review; useful for mapping consistency and gaps, not automatically a pooled causal estimate. (US Preventive Services Task Force 2023, PMID 37338872)

  • Maurus I 2024 — EPA guidance on lifestyle interventions for adults with severe mental illness: A meta-review of the evidence. Systematic review; useful for mapping consistency and gaps, not automatically a pooled causal estimate. (Maurus I 2024, PMID 39655999)

  • MacQueen G 2017 — Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults. Systematic review; useful for mapping consistency and gaps, not automatically a pooled causal estimate. (MacQueen G 2017, PMID 27554483)

  • Zhou S 2023 — Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Zhou S 2023, PMID 37422714)

  • Kishi T 2024 — Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Kishi T 2024, PMID 38219278)

  • Koesters M 2017 — Vortioxetine for depression in adults. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Koesters M 2017, PMID 28677828)

  • Krause M 2019 — Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Krause M 2019, PMID 31327506)

  • Du Y 2024 — Efficacy and acceptability of anti-inflammatory agents in major depressive disorder: a systematic review and meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Du Y 2024, PMID 38863604)

  • Yan Y 2022 — Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Yan Y 2022, PMID 35993319)

  • Papadimitropoulou K 2017 — Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Papadimitropoulou K 2017, PMID 28035869)

  • Gartlehner G 2008 — Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Gartlehner G 2008, PMID 19017592)

  • McIntyre RS 2026 — Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (McIntyre RS 2026, PMID 42090141)

  • Xie J 2026 — Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Xie J 2026, PMID 42490943)

  • Kato M 2021 — Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Kato M 2021, PMID 32704061)

  • Hansen R 2008 — Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Hansen R 2008, PMID 18832497)

  • Kaymaz N 2008 — Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Kaymaz N 2008, PMID 19193343)

International positions added in the 2026 deepening sweep

Body Structural emphasis Position that can diverge from North American/UK framing
RANZCP 2020 formulation and multiple treatment “actions” across mood disorders organizes care less as a single ranked ladder and more as combined actions (Malhi 2021, PMID 33353391; Malhi 2020, PMID 33320412)
German NVL/S3 shared decisions and stepped psychotherapy/pharmacotherapy in the German system exact delivery recommendations assume German service pathways (Härter 2023, PMID 37070271)
AFPBN/FondaMental 2024 partial response and TRD sequencing greater algorithmic detail after failure, with expert consensus filling comparative gaps (Yrondi 2025, PMID 38369426)
Korean Medication Algorithm 2025 medication-focused sequencing under Korean availability consensus rankings may differ from CANMAT/NICE because formularies and expert weighting differ (Kim 2025, PMID 41139602)
BAP 2015 evidence-based antidepressant pharmacology remains influential but predates multiple rapid-acting agents and newer withdrawal syntheses (Cleare 2015, PMID 25969470)
WFSBP pharmacology summary international biological-treatment synthesis older evidence base makes it a legacy comparator, not a current pipeline guide (Bauer 2017, PMID 28367707)
Japanese Society of Mood Disorders 2012 national MDD treatment framework important regional representation but now a legacy document requiring update checks (Ogasawara 2012, PMID 23037606)

These additions sharpen an important distinction: agreement that psychotherapy and antidepressants are effective does not imply agreement on ordering, combination thresholds, monitoring burden, or when device/rapid-acting treatments enter the pathway.

Open questions

  • Would head-to-head sequencing trials collapse major line-ranking disagreements?
  • How should guidelines incorporate antidepressant withdrawal evidence (Davies 2019, PMID 30292574)?
  • Which recommendations remain feasible in low-resource systems with large treatment gaps (Thornicroft 2017, PMID 27908899)?
  • How frequently should rapidly changing ketamine, psychedelic, and accelerated-TMS evidence trigger updates?

References

  1. Lam RW, et al. CANMAT 2023 Update on Clinical Guidelines for MDD. Canadian Journal of Psychiatry. 2024. PMID 38711351
  2. McQuaid JR, et al. Synopsis of the 2022 VA/DoD MDD Guideline. Annals of Internal Medicine. 2022. PMID 36122380
  3. Qaseem A, et al. ACP Living Clinical Guideline for Acute MDD. Annals of Internal Medicine. 2023. PMID 36689752
  4. Marx W, et al. Lifestyle-based mental health care guidelines for MDD. World Journal of Biological Psychiatry. 2023. PMID 36202135
  5. Swainson J, et al. CANMAT recommendations for racemic ketamine. Canadian Journal of Psychiatry. 2021. PMID 33174760
  6. McClintock SM, et al. Consensus recommendations for rTMS in depression. Journal of Clinical Psychiatry. 2018. PMID 28541649
  7. Davies J, Read J. Antidepressant withdrawal effects. Addictive Behaviors. 2019. PMID 30292574
  8. Thornicroft G, et al. Undertreatment of MDD in 21 countries. British Journal of Psychiatry. 2017. PMID 27908899
  9. Fregni F, et al. Evidence-Based Guidelines and Secondary Meta-Analysis for the Use of Transcranial Direct Current Stimulation in Neurological and Psychiatric Disorders. The international journal of neuropsychopharmacology. 2021;24:256-313. PMID 32710772
  10. US Preventive Services Task Force, et al. Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329:2057-2067. PMID 37338872
  11. Maurus I, et al. EPA guidance on lifestyle interventions for adults with severe mental illness: A meta-review of the evidence. European psychiatry : the journal of the Association of European Psychiatrists. 2024;67:e80. PMID 39655999
  12. MacQueen G, et al. Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2017;62:11-23. PMID 27554483
  13. Zhou S, et al. Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep. 2023;46:zsad177. PMID 37422714
  14. Kishi T, et al. Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. Neuropsychopharmacology reports. 2024;44:165-175. PMID 38219278
  15. Koesters M, et al. Vortioxetine for depression in adults. The Cochrane database of systematic reviews. 2017;7:CD011520. PMID 28677828
  16. Krause M, et al. Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2019;29:1003-1022. PMID 31327506
  17. Du Y, et al. Efficacy and acceptability of anti-inflammatory agents in major depressive disorder: a systematic review and meta-analysis. Frontiers in psychiatry. 2024;15:1407529. PMID 38863604
  18. Yan Y, et al. Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. Psychological medicine. 2022;52:2224-2231. PMID 35993319
  19. Papadimitropoulou K, et al. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Current medical research and opinion. 2017;33:701-711. PMID 28035869
  20. Gartlehner G, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Annals of internal medicine. 2008;149:734-50. PMID 19017592
  21. McIntyre RS, et al. Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. JAMA psychiatry. 2026;83:741-750. PMID 42090141
  22. Xie J, et al. Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis. Frontiers in psychiatry. 2026;17:1774549. PMID 42490943
  23. Kato M, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Molecular psychiatry. 2021;26:118-133. PMID 32704061
  24. Hansen R, et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatric services (Washington, D.C.). 2008;59:1121-30. PMID 18832497
  25. Kaymaz N, et al. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. The Journal of clinical psychiatry. 2008;69:1423-36. PMID 19193343
  26. Malhi GS, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian and New Zealand Journal of Psychiatry. 2021;55:7-117. PMID 33353391
  27. Malhi GS, et al. The 2020 RANZCP guideline: major depression summary. Bipolar Disorders. 2020;22:788-804. PMID 33320412
  28. Bauer M, et al. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. International Journal of Psychiatry in Clinical Practice. 2017;21:166-176. PMID 28367707
  29. Cleare A, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: BAP revision. Journal of Psychopharmacology. 2015;29:459-525. PMID 25969470
  30. Yrondi A, et al. AFPBN guidelines for partially responsive and treatment-resistant depression: update 2024. L'Encéphale. 2025;51:26-38. PMID 38369426
  31. Kim NY, et al. Korean Medication Algorithm for Depressive Disorder 2025, fifth revision. Clinical Psychopharmacology and Neuroscience. 2025;23:683-706. PMID 41139602
  32. Härter M, et al. Clinical practice guideline: diagnosis and treatment of unipolar depression. Deutsches Ärzteblatt International. 2023;120:355-361. PMID 37070271
  33. Ogasawara K. Review of the Japanese Society of Mood Disorders MDD treatment guideline. Brain and Nerve. 2012;64:1159-1165. PMID 23037606